Qizhong Lu, Donghui Yang, Hexian Li, Zhixiong Zhu, Zongliang Zhang, Yongdong Chen, Nian Yang, Jia Li, Zeng Wang, Ting Niu, Aiping Tong
In the treatment of relapsed or refractory multiple myeloma patients, BCMA-directed autologous CAR-T cells have showed excellent anti-tumor activity. However, their widespread application is limited due to the arguably cost and time-consuming. Multiple myeloma cells highly expressed CD47 molecule and interact with the SIRPα ligand on the surface of macrophages, in which evade the clearance of macrophages through the activation of "don't eat me" signal. In this study, a BCMA-directed universal CAR-T cells, BC404-UCART, secreting a CD47-SIRPα blocker was developed using CRISPR/Cas9 gene-editing system...
January 22, 2024: Cancer Letters